OncoMatch/Clinical Trials/NCT04155034
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
Is NCT04155034 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for extensive stage lung small cell carcinoma.
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage III, IV
limited-stage (LS)-SCLC; extensive-stage (ES)-SCLC
Performance status
ZUBROD 0–2
Prior therapy
Must have received: platinum-based chemotherapy — first-line
Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy ... Patients with extensive-stage (ES)-SCLC must have completed platinum-based chemotherapy
Must have received: thoracic radiotherapy or definitive surgical resection — limited-stage SCLC
Patients with limited-stage (LS)-SCLC must have completed platinum-based chemotherapy and either definitive thoracic radiotherapy (including stereotactic body radiation therapy [SBRT] for early-stage T1-2 N0 M0 disease who do not undergo surgery) or definitive surgical resection
Cannot have received: radiotherapy to the brain or whole brain radiotherapy
Exception: prior stereotactic radiosurgery for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis
Patient must not have received prior radiotherapy to the brain or whole brain radiotherapy. Patients who have undergone prior stereotactic radiosurgery for benign tumors or conditions (e.g., acoustic neuroma, grade I meningioma, trigeminal neuralgia) may be considered on a case-by-case basis
Lab requirements
Kidney function
No contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
Liver function
No severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease
Cardiac function
No unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to randomization; no transmural myocardial infarction within 6 months prior to randomization
No severe active comorbidities, defined as follows: Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to randomization; Transmural myocardial infarction within 6 months prior to randomization; Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease; No contraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- Katmai Oncology Group · Anchorage, Alaska
- Fairbanks Memorial Hospital · Fairbanks, Alaska
- University of Arizona Cancer Center-Orange Grove Campus · Tucson, Arizona
- University of Arizona Cancer Center-North Campus · Tucson, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify